TY - JOUR
TI - The prognostic role of CD5 negativity in B-cell chronic lymphocytic
leukaemia: a case-control study
AU - Efstathiou, S
AU - Tsioulos, D
AU - Zacharos, I
AU - Tsiakou, A and
AU - Mastorantonakis, S
AU - Salgami, E
AU - Katirtzoglou, N
AU - Psarra, A and
AU - Roussou, P
JO - Haematologia
PY - 2002
VL - 32
TODO - 3
SP - 209-218
PB - VSP BV
SN - 0017-6559, 1568-5594
TODO - 10.1163/15685590260461020
TODO - CD5; chronic lymphocytic leukaemia; prognosis
TODO - B cells in chronic lymphocytic leukaemia (CLL) usually express the CD5
antigen, which appears to participate in the pathogenesis of autoimmune
phenomena. However, 7-20% of B-CLL patients are CD5(-). The aim of this
study was to assess whether CD5 expression could be used as a
discriminating factor for two subgroups of B-CLL. Twenty-nine CD5(-)
B-CLL patients were compared in terms of clinico-biological
characteristics and survival with a control group of 29 sex and
age-matched, consecutive CD5(+) B-CLL subjects. B-CLL was considered to
be CD5(-) when less than 5% of mononuclear cells expressed CD5 after
subtraction of the number of T cells. Splenomegaly, lymph node
involvement, and haemolytic anemia were found in CD5(+) patients in a
significantly higher proportion than in their CD5- counterparts, who
presented with an earlier stage of disease. CD5- patients had a median
survival of 97.2 (22-130) months, exceeding CD5(+) subjects
significantly [84.0 (19-120) months, p = 0.0025]. CD5(-) patients
seemingly present with milder disease and have a favourable prognosis
compared with the vast majority of B-CLL patients who express CD5.
ER -